

Curriculum vitae di Giovanni Palladini

Nato a Carpi (Modena), il 10 febbraio 1973.

Coniugato, un figlio.

First Certificate in English, 1988.

Certificate of Proficiency in English, 1990.

Alunno – Almo Collegio Borromeo, Pavia.

Dal 1994 collaborazione con il Prof. Merlini nel Centro per l'Amiloidosi del Policlinico San Matteo di Pavia.

Laurea in Medicina e Chirurgia (110/110 e lode), Università di Pavia (1997).

Specializzazione in Medicina Interna (50/50 e lode), Università di Pavia (2002).

Dottorato di Ricerca in Medicina Interna, Università di Pavia (2007).

Special Project Associate, Mayo Clinic, Rochester, MN, USA (1999).

Corso di Perfezionamento in Sperimentazione Clinica, Università di Milano (2000-2001).

Contratto di collaborazione presso il Centro per lo Studio e la Cura delle Amiloidosi Sistemiche – Policlinico San Matteo, Pavia (2002-2004).

Dirigente Medico presso il Centro per lo Studio e la Cura delle Amiloidosi Sistemiche – Policlinico San Matteo, Pavia (2005-2008).

Ricercatore presso il Dipartimento di Medicina Molecolare dell'Università di Pavia convenzionato presso la Fondazione IRCCS Policlinico San Matteo (dal 2008).

Società Italiana per l'Amiloidosi (dal 1999), Tesoriere (dal 2008).

Società Italiana di Medicina Interna (dal 2000).

International Amyloidosis Society (dal 2001, *Member at large* dal 2010).

American Society of Hematology (dal 2011).

Membro dell'Editorial Board di "AMYLOID" (dal 2005).

Ha svolto attività di revisore per: *Acta Haematologica, Aging Health, American Journal of Cardiology, American Journal of Hematology, Amyloid, Blood, British Journal of Haematology, Bone Marrow Transplantation, Chest, Clinical and Experimental Rheumatology, Clinical Medicine and Research, European Journal of Neurology, European Heart Journal, Expert Review of Cardiovascular Therapy, Haematologica, Hematology, Nephrology Dialysis and Transplantation, Orphanet Journal of Rare Diseases, Rheumatology, Tumori.*

Premi

2002 Premio Fichera, Università di Pavia.

2002 Società Italiana di Cardiologia, Fondazione Aventis.

2002 Società Italiana di Cardiologia per Giovani Ricercatori.

2002 Travel Award, American Society of Hematology.

2003 Premio Angelo Monteverde, Società Italiana di Medicina Interna.

2003 Società Italiana di Medicina Interna, Fondazione Aventis.

2004 Giovani Ricercatori, Fondazione Berlucci.

2005 – 2007 Alunno Speciale MINTAS, Collegio Ghislieri, Pavia.

Il Dr. Palladini è autore di 87 pubblicazioni su riviste internazionali a controllo redazionale:

1. Wechalekar AD, Schoenland S, Kastiris E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G. A European collaborative study of treatment outcomes in 346 Patients with Stage III AL amyloidosis. *Blood* 2013 (in press).
2. Palladini G, Merlini G. Diagnostic Challenges of Amyloidosis in Waldenström Macroglobulinemia. *Clin Lymphoma Myeloma Leuk* 2013 (in press).
3. Perfetti V, Palladini G, De Amici M, Livraghi L, Pedrazzoli P, Merlini G. Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. *Ann Hematol* (in press).
4. Mussinelli R, Salinaro F, Alogna A, Boldrini M, Raimondi A, Musca F, Palladini G, Merlini G, Perlini S. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. *Ann Noninvasive Electrocardiol* 2012 (in press).

5. Boldrini M, Salinaro F, Mussinelli R, Raimondi A, Alogna A, Musca F, Palladini G, Merlini G, Perlini S. Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis 2012 (in press).
6. Perlini S, Salinaro F, Cappelli F, Perfetto F, Bergesio F, Alogna A, Mussinelli R, Boldrini M, Raimondi A, Musca F, Palladini G, Merlini G. Prognostic value of fragmented QRS in cardiac AL amyloidosis. *Int J Cardiol* 2012 (in press).
7. Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Quarleri L, Vadacca G, Albertini R, Merlini G. Serum prealbumin: An independent marker of short-term energy intake in the presence of multiple-organ disease involvement. *Nutrition* 2013; 29: 580-582.
8. Gatt ME, Palladini G. Light chain amyloidosis 2012: a new era. *Br J Haematol* 2013; 160: 582-598.
9. Palladini G, Russo P, Milani P, Foli A, Lavatelli F, Nuvolone M, Perlini S, Merlini G. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. *Haematologica* 2013; 98: 433-436.
10. Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M, Grigioni F, Leone O, Cappelli F, Palladini G, Rimessi P, Ferlini A, Arpesella G, Pinna AD, Merlini G, Perlini S. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. *Eur Heart J* 2013; 34: 520-528.
11. Palladini G, Comenzo RL. The challenge of systemic immunoglobulin light-chain amyloidosis (AL). *Subcell Biochem* 2012; 65: 609-642.
12. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar AD, Hawkins PN, Schönland S, Hegenbart U, Comenzo R, Kastritis S, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in AL amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. *J Clin Oncol* 2012; 30: 4541-4549.
13. Merlini G, Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined significance. *Hematology Am Soc Hematol Educ Program* 2012; 2012: 595-603.
14. Comenzo RL, Reece D, Palladini G, Seldin D, Sancharawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis. *Leukemia* 2012; 26: 2317-2325.
15. Gioia R, Panaroni C, Besio R, Palladini G, Merlini G, Giansanti V, Scovassi I, Villani S, Villa I, Villa A, Vezzoni P, Marini JC, Tenni R, Rossi A, Forlino A. Impair osteoblastogenesis in a murine model of dominant osteogenesis imperfecta, a new target for OI pharmacological therapy. *Stem Cells* 2012; 30: 1465-1476.
16. Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G, Perlini S, Saraiva MJ, Merlini G. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. *Amyloid* 2012; 19 Suppl 1: 34-36.
17. Palladini G, Foli A, Milani P, Russo P, Albertini L, Lavatelli F, Obici L, Perlini S, Moratti R, Merlini G. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. *Am J Hematol* 2012; 87: 465-471.
18. Klersy C, d'Eril GV, Barassi A, Palladini G, Comelli M, Moratti R, Albertini R, Merlini G. Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide. *Clin Chim Acta* 2012; 413: 544-547.
19. Brambilla F, Lavatelli F, Di Silvestre D, Valentini V, Rossi R, Palladini G, Obici L, Verga L, Mauri P, Merlini G. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. *Blood* 2012; 119: 1844-1847.
20. Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, Montagna E, Russo P, Foli A, Milani P, Lavatelli F, Merlini G. Nutritional status and quality of life in outpatients with systemic immunoglobulin light-chain amyloidosis (AL) at diagnosis. *Ann Hematol* 2012; 91: 399-406.
21. Perfetti V, Palladini G, Casarini S, Navazza V, Rognoni P, Obici L, Invernizzi R, Perlini S, Klersy C, Merlini G. The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. *Blood* 2012; 119: 144-150.
22. Palladini G, Russo P, Foli A, Milani P, Lavatelli F, Obici L, Nuvolone M, Brugnatelli S, Invernizzi R, Merlini G. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide. *Ann Hematol* 2012; 91: 89-92.
23. Palladini G, Barassi A, Perlini S, Milani P, Foli A, Russo P, Albertini R, Obici L, Lavatelli F, Sarais G, Casarini S, Moratti R, Melzi d'Eril GV, Merlini G. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. *Amyloid* 2011; 8: 216-221.
24. Dubrey SW, Reece DE, Sancharawala V, Hegenbart U, Merlini G, Palladini G, Femand JP, Vescio RA, Bladé J, Heffner LT, Hassoun H, Liu X, Enny C, Ramaswami P, Elsayed Y, van de Velde H, Mortimer S, Cakana A, Comenzo RL, for the VELCADE CAN2007 Study Group. Bortezomib in a Phase 1 Trial for Patients with Relapsed AL Amyloidosis: Cardiac Responses and Overall Effects. *QJM*. 2011; 104: 957-970.
25. Palladini G, Merlini G. Uniform risk-stratification and response criteria are paving the way towards evidence-based treatment of AL amyloidosis. *Oncology (Williston Park)* 2011; 25: 633, 637-8.
26. Ferrari R, Caffi E, Quagliani S, Stefanelli M, Russo P, Palladini G, Lavatelli F, Merlini G. AMICA: an electronic patient record specifically designed for an amyloidosis network. *Amyloid* 2011; 18 Suppl 1: 231-233.

27. Panzarasa S, Quaglini S, Ferrari R, Stefanelli M, Foli A, [Palladini G](#), Russo P, Lavatelli F. A workflow management system for the biological samples exchange within the amyloidosis network. *Amyloid* 2011; 18 Suppl 1: 228-230.
28. Perlini S, Musca F, Salinaro F, Fracchioni I, [Palladini G](#), Obici L, Albertini R, Moratti R, Lavatelli F, Palladini G, Rapezzi C, Merlini G. Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis. *Amyloid* 2011; 18 Suppl 1: 91-92.
29. Russo P, [Palladini G](#), Foli A, Zenone Bragotti L, Milani P, Nuvolone M, Obici L, Perfetti V, Brugnatelli S, Invernizzi R, Merlini G. Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients. *Amyloid* 2011; 18 Suppl 1: 87-88.
30. Foli A, [Palladini G](#), Caporali R, Verga L, Morbini P, Obici L, Russo P, Sarais G, Donadei S, Montecucco C, Merlini G. The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. *Amyloid* 2011; 18 Suppl 1: 75-77.
31. Lavatelli F, Valentini V, [Palladini G](#), Verga L, Russo P, Foli A, Obici L, Sarais G, Perfetti V, Casarini S, Merlini G. Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits. *Amyloid* 2011; 18 Suppl 1: 59-61.
32. Valentini V, Lavatelli F, Obici L, Donadei S, Perlini S, [Palladini G](#), Merlini G. Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations. *Amyloid* 2011; 18 Suppl 1: 56-58.
33. Reece D, Hegenbart U, Sancharawala V, Merlini G, [Palladini G](#), Blade J, Femand JP, Hassoun H, Heffner L, Vescio R, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase-1/2 study. *Blood* 2011; 118: 865-873.
34. [Palladini G](#), Foli A, Russo P, Milani P, Obici L, Lavatelli F, Merlini G. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib and dexamethasone. *Clin Lymphoma Myeloma Leuk* 2011; 11: 143-145.
35. Lavatelli F, Brambilla F, Valentini V, Rognoni P, Casarini S, Di Silvestre D, Perfetti V, [Palladini G](#), Sarais G, Mauri P, Merlini G. A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. *Biochim Biophys Acta* 2011; 1814: 409-419.
36. [Palladini G](#), Merlini G. Transplantation versus conventional-dose therapy for amyloidosis. *Curr Op Oncol* 2011; 23: 214-220.
37. [Palladini G](#), Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G, Perlini S, Albertini R, Russo P, Foli A, Zenone Bragotti L, Obici L, Moratti R, Melzi d'Eril GV, Merlini G. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. *Blood* 2010; 116: 3426-30.
38. Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, [Palladini G](#). Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. *J Clin Oncol* 2010; 28: 1031-1037.
39. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RMT, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, [Palladini G](#), Salinaro F, Musca F, Obici L, Branzi A, Perlini S. The systemic cardiac amyloidoses: disease profiles and clinical courses of the three main etiologic forms. *Circulation* 2009; 120: 1203-1212.
40. [Palladini G](#), Merlini G. Current treatment of AL amyloidosis. *Haematologica* 2009; 94: 1044-1048.
41. Reece D, Sancharawala V, Hegenbart U, Merlini G, [Palladini G](#), Femand JP, Vescio R, Liu K, Elsayed Y, Cakana A, Comenzo R. Weekly and twice-weekly bortezomib in patients with systemic AL-amyloidosis: results of a phase 1 dose-escalation study. *Blood* 2009; 114: 1489-1497.
42. [Palladini G](#), Russo P, Bosoni T, Sarais G, Lavatelli F, Foli A, Zenone Bragotti L, Perfetti V, Obici L, Bergesio F, Albertini R, Moratti R, Merlini G. AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity. *Clin Lymphoma Myeloma* 2009; 9: 80-83.
43. Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, Orsi A, Pasqualetto E, Mezghrani A, Calbi V, [Palladini G](#), Giuliani N, Anderson KC, Sitia R, Cenci S. The proteasome load vs. capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. *Blood* 2009; 113: 3040-3049.
44. [Palladini G](#), Russo P, Bosoni T, Verga L, Sarais L, Lavatelli L, Nuvolone M, Obici L, Casarini S, Donadei S, Albertini R, Righetti G, Marini M, Graziani MS, Melzi D'Eril GV, Moratti R, Merlini G. Identification of amyloidogenic light chains requires the combination of serum free light chain assay with immunofixation of serum and urine. *Cl Chem* 2009; 55: 499-504.
45. [Palladini G](#), Russo P, Lavatelli F, Nuvolone M, Albertini R, Bosoni T, Perfetti V, Obici L, Perlini S, Moratti R, Merlini G. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone and thalidomide. *Ann Hematol* 2009; 88: 347-350.
46. Piccoli GB, Soragna G, [Palladini G](#), Magnano A, Sargiotto A, Picciotto G, Terzolo M. End-stage renal failure due to amyloidosis and recurrent fever on dialysis--is there a link? *Nephrol Dial Transplant* 2008; 23: 2419-2421.
47. Merlini G, [Palladini G](#). Amyloidosis: is a cure possible? *Ann Oncol* 2008; 19 (Suppl 4): iv63-66.
48. Caporali R, Bonacci E, Epis O, [Palladini G](#), Bobbio-Pallavicini F, Morbini P, Montecucco C. Safety and usefulness of minor salivary gland biopsy: retrospective analysis of 502 procedures performed at a single center. *Arthritis Rheum* 2008; 59: 714-720.

49. Meijer JM, Schonland SO, Palladini G, Merlini G, Hegenbart U, Ciocca O, Perfetti V, Leijnsma MK, Bootsma H, Hazenberg BPC. Sjögren's syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity? *Arth Reum* 2008; 58: 1992-1999.
50. Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, Di Palma AM, Gallo M, Rosati A, Tosi PL, Salvadori M. Renal involvement in systemic amyloidosis. *Nephrol Dial Transplant* 2008; 23: 941-951.
51. Guabello G, Brunetti L, Palladini G, Musumeci S, Lovati E, Perfetti V. Paraneoplastic Cushing's Syndrome and nephrotic syndrome in a patient with disseminated small cell lung cancer. *Am J Clin Oncol* 2008; 31: 102-103.
52. Navazza V, Gabba S, Alfieri A, Giorgetti S, Marchese L, Palladini G, Mattevi A, Ascari E, Caporali R, Montecucco C, Merlini G, Perfetti V. Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocryoglobulins. *Mol Immunol* 2008; 45: 1519-1524.
53. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy? *Haematologica* 2007; 92: 1302-1307.
54. Ghio S, Perlini S, Palladini G, Ajmone Marsan N, Faggiano G, Vezzoli M, Klersy C, Campana C, Merlini G, Tavazzi L. Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. *Eur J Heart Fail* 2007; 9: 808-813.
55. Palladini G, Russo P, Nuvolone M, Lavatelli F, Perfetti V, Obici L, Merlini G. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. *Blood* 2007; 110: 787-788.
56. Bergesio F, Ciciani AM, Santostefano M, Brugnano R, Manganaro M, Palladini G, Di Palma AM, Gallo M, Tosi PL, Salvadori M. Renal involvement in systemic amyloidosis--an Italian retrospective study on epidemiological and clinical data at diagnosis. *Nephrol Dial Transplant*. 2007; 22: 1608-1618.
57. Perfetti V, Palladini G, Brunetti L, Sgarella A, Brugnattelli S, Gobbi PG, Corazza GR. Bortezomib-induced paralytic ileus is a potential gastrointestinal side-effect of this first-in-class anti-cancer proteasome inhibitor. *Eur J Gastroenterol Hepatol*. 2007; 19: 599-601.
58. Bellotti V, Nuvolone M, Giorgetti S, Obici L, Palladini G, Russo P, Lavatelli F, Perfetti V, Merlini G. The workings of the amyloid diseases. *Ann Med* 2007; 39: 200-207.
59. Invernizzi R, Palladini G, Benatti C, Travaglio E, Nuvolone M, Merlini G. Bone marrow amyloidosis. *Haematologica* 2006; 91 (5 Suppl): E1M01.
60. Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L, Magni M, Brunetti L, Gianni AM, Merlini G. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. *Haematologica* 2006; 91: 1635-1643.
61. Palladini G, Perfetti V, Merlini G. Therapy and management of systemic AL (primary) amyloidosis. *Swiss Med Wkly* 2006; 136: 715-720.
62. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, Bradwell AR, Melzi D'Eril GV, Fogari R, Moratti R, Merlini G. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis. *Blood* 2006; 107: 3854-3858.
63. Caccialanza R, Palladini G, Klersy C, Cena H, Vagia C, Cameletti B, Russo P, Lavatelli F, Merlini G. Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis (AL). *Am J Clin Nutr* 2006; 83: 350-354.
64. Semino A, Danova M, Perlini S, Palladini G, Riccardi A, Perfetti V. Unusual manifestation of disseminated neoplasia at presentation: right-sided heart failure due to a massive cardiac metastasis and autoimmune thrombocytopenia in pleomorphic rhabdomyosarcoma of the adult. *Am J Clin Oncol* 2006; 29: 102-103.
65. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. *Biochim Biophys Acta* 2005; 1753: 11-22.
66. Obici L, Demarchi A, de Rosa G, Bellotti V, Marciano S, Donadei S, Arbustini E, Palladini G, Diegoli M, Genovese E, Ferrari G, Coverlizza S, Merlini G. A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. *Ann Neurol*. 2005; 58: 639-644.
67. Palladini G, Kyle RA, Larson DR, Therneau TM, Merlini G, Gertz MA. Multicenter versus single center approach to rare diseases: the model of systemic light chain amyloidosis. *Amyloid* 2005; 12: 120-126.
68. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, Invernizzi R, Comotti B, Merlini G. The combination of thalidomide and intermediate dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). *Blood* 2005; 105: 2949-2951.
69. Obici L, Manno C, Onetti Muda A, Picco P, D'Osualdo A, Palladini G, Avanzini MA, Torres D, Marciano S, Merlini G. First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. *Arthritis Rheum* 2004; 50: 2966-2969.
70. Perfetti V, Colli Vignarelli M, Palladini G, Navazza V, Giachino C, Merlini G. Insights into the regulation of immunoglobulin light chain gene rearrangements via analysis of the kappa light chain locus in lambda myeloma. *Immunology* 2004; 112: 420-427.
71. Obici L, Palladini G, Giorgetti S, Bellotti V, Gregorini G, Arbustini E, Verga L, Marciano S, Donadei S, Perfetti V, Calabresi L, Bergonzi C, Scolari F, Merlini G. Liver biopsy discloses a new apolipoprotein AI hereditary amyloidosis in several unrelated Italian families. *Gastroenterology* 2004; 126: 1416-1422.

72. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, Cavallero G, Rustichelli R, Virga G, Merlini G. The association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis ineligible for stem cell transplantation. *Blood* 2004; 103: 2936-2938.
73. Perfetti V, Palladini G, Merlini G. Immune mechanisms of AL amyloidosis. *Drug Discov Today* 2004; 1: 365-373.
74. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, Melzi D'Eril G, Moratti R, Merlini G. Serum N-terminal pro Brain Natriuretic Peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. *Circulation* 2003; 107: 2440-2445.
75. Merlini G, Baldini L, Brogna C, Comelli M, Goldaniga M, Palladini G, Lambertenghi Deliliers G, Gobbi PG. Prognostic factors in symptomatic Waldenström macroglobulinemia. *Sem Oncol* 2003; 30: 211-215.
76. Bernardi L, Passino C, Porta C, Anesi E, Palladini G, Merlini G. Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension? *Heart* 2002; 88: 615-621.
77. Palladini G, Obici L, Merlini G. Hereditary amyloidosis. *New Engl J Med* 2002; 347: 1206-1207.
78. Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. *Amyloid* 2002; 9: 108-114.
79. Perfetti V, Casarini S, Palladini G, Colli Vignarelli M, Klersy C, Diegoli M, Ascari E, Merlini G. Analysis of $V\lambda$ - $J\lambda$ expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies $3r$ (λ III) as a new amyloid-associated germline gene segment. *Blood* 2002; 100: 948-953.
80. Gertz MA, Lacy MQ, Dispenzieri A, Cheson B, Barlogie B, Kyle RA, Palladini G, Geyer S, Merlini G. A multicenter phase II trial of 4'-iodo-4'-deoxydoxorubicin in primary amyloidosis (AL). *Amyloid* 2002; 9: 24-30.
81. Merlini G, Bellotti V, Andreola A, Palladini G, Obici L, Casarini S, Perfetti V. Protein aggregation. *Clin Chem Lab Med* 2001; 39 (11): 1065-1075.
82. Anesi E, Palladini G, Perfetti V, Arbustini E, Obici L, Merlini G. Therapeutic advances demand better typing of amyloid deposits. *Am J Med* 2001; 111 (3): 243-244.
83. Palladini G, Malamani G, Cò F, Pistorio A, Recusani F, Anesi E, Garini P, Merlini G. Holter monitoring in AL amyloidosis: prognostic implications. *Pacing Clin Electrophysiol* 2001; 24: 1228-1233.
84. Palladini G, Anesi E, Perfetti V, Obici L, Invernizzi R, Balduini C, Ascari E, Merlini G. A modified high-dose dexamethasone regimen for primary systemic amyloidosis. *British Journal of Haematology* 2001; 113 (4): 1044-1046.
85. Casiraghi MA, De Paoli A, Assi A, Palladini G, Lavazza MT, Beretta A, Gualdoni G, Beretta R. Hepatic amyloidosis with light chain deposition disease. A rare association. *Dig Liver Dis* 2000; 32 (9): 795-798.
86. Gamba G, Montani N, Anesi E, Palladini G, Capezzer M, Soldavini E, Merlini G. Clotting alterations in primary systemic amyloidosis. *Haematologica* 2000; 85(3): 289-292.
87. Gamba G, Montani N, Anesi E, Palladini G, Lorenzutti F, Perfetti V, Merlini G. Abnormalities in thrombin-antithrombin pathway in primary systemic amyloidosis. *Amyloid* 1999; 6(4): 273-7.